A New Medical Device Rigeneracons Allows to Obtain Viable Micro-Grafts From Mechanical Disaggregation of Human Tissues.
Autologous graft is considered the gold standard of graft materials; however, this approach is still limited due to both small amount of tissue that can be collected and to reduced cell viability of cells that can be obtained. The aim of this preliminary study was to demonstrate the efficacy of an innovative medical device called Rigeneracons® (CE certified Class I) to provide autologous micro-grafts immediately available to be used in the clinical practice. Moreover, Rigeneracons® is an instrument able to create micro-grafts enriched of progenitors cells which maintain their regenerative and differentiation potential. We reported preliminary data about viability cell of samples derived from different kind of human tissues, such as periosteum, cardiac atrial appendage biopsy, and lateral rectus muscle of eyeball and disaggregated by Rigeneracons®. In all cases we observed that micro-grafts obtained by Rigeneracons® displayed high cell viability. Furthermore, by cell characterization of periosteum samples, we also evidenced an high positivity to mesenchymal cell markers, suggesting an optimal regenerative potential.
Human Brain Wave srl, Turin, Italy.
Letizia
L
Trovato
Research Center of Regenerative Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Manuela
M
Monti
Immunohaematology and Transfusion Service, Apheresis and Cell Therapy Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Claudia
C
Del Fante
Immunohaematology and Transfusion Service, Apheresis and Cell Therapy Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Marila
M
Cervio
Faculty of Medicine, Department of Pharmacology, University of Helsinki, Helsinki, Finland.
Milla
M
Lampinen
Department of Neuroscience, Reproductive and Odontostomatologic Sciences, Federico II University of Naples, Naples, Italy.
Lucia
L
Ambrosio
Research Center of Regenerative Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Carlo Alberto
CA
Redi
Immunohaematology and Transfusion Service, Apheresis and Cell Therapy Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Cesare
C
Perotti
Faculty of Medicine, Department of Pharmacology, University of Helsinki, Helsinki, Finland.
Esko
E
Kankuri
Department of Neuroscience, Reproductive and Odontostomatologic Sciences, Federico II University of Naples, Naples, Italy.
Gennaro
G
Ambrosio
Department of Clinico Surgical, Diagnostic and Pediatric Sciences, School of Dentistry, University of Pavia, Pavia, Italy.
Ruggero
R
Rodriguez Y Baena
Department of Research, Istituto Nazionale Tumori-Fondazione G. Pascale, Naples, Italy.
Giuseppe
G
Pirozzi
Human Brain Wave srl, Turin, Italy.
Antonio
A
Graziano
D016025:Bone Transplantation / Q000295:instrumentation*; D002470:Cell Survival / Q000502:physiology; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000166:cytology*; D010521:Periosteum / Q000166:cytology*; D014182:Transplantation, Autologous / Q000295:instrumentation* / Q000379:methods; D014184:Transplantation, Homologous / Q000295:instrumentation*